Treatment of Active Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection: a Randomized, Double-blind, Multicentral Clinical Trial to Investigate the Efficacy and Safety of Yisaipu

Trial Profile

Treatment of Active Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection: a Randomized, Double-blind, Multicentral Clinical Trial to Investigate the Efficacy and Safety of Yisaipu

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Spondylarthritis
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jun 2017 Results (n=123) assessing efficacy and safety presented at the 18th Annual Congress of the European League Against Rheumatism.
    • 16 Apr 2016 Planned End Date changed from 1 Apr 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.
    • 16 Apr 2016 Planned primary completion date changed from 1 Jan 2016 to 1 Dec 2016, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top